Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.22.4
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:    
Research and development $ 16,087,168 $ 4,627,386
General and administrative 7,292,744 3,663,707
Total operating expenses 23,379,912 8,291,093
Loss from operations (23,379,912) (8,291,093)
Other income (expense):    
Change in fair value of financial instruments 4,176,767 (1,095,636)
Interest expense on convertible debt (282,064) (416,286)
Gain on extinguishment of convertible debt and derivative liability 1,307,421  
Other income 115,525 12,909
Total other income (expense), net 5,317,649 (1,499,013)
Net loss (18,062,263) (9,790,106)
Other comprehensive loss    
Foreign currency translation adjustment (7,450) (137,188)
Comprehensive loss $ (18,069,713) $ (9,927,294)
Net loss per share, basic $ (2.41) $ (1.69)
Net loss per share, diluted $ (2.41) $ (1.69)
Weighted-average shares outstanding of common shares, basic 7,502,609 5,785,617
Weighted-average shares outstanding of common shares, diluted 7,502,609 5,785,617